perhaps the others already had a run with PD-1 PD-L1

perhaps the others already had a run with PD-1 PD-L1 inhibitors and were onto the next in line salvage therapies. no one in those circumstance had PD-L1 on the radar... plus, the ones that didnt get it were soon dead. meaning, there wasnt a lot of time to "notice" any PD-L1 change. that's what seems logical. the 5 had not had ICI before. would be interesting to know though whether the docs for those 5 noticed PD-L1 being elevated and therefore went to the ICI. ideally you would think if that were the case they might reach out to someone at cytodyn or amarex or another clinical site. probably just circumstance rather than a data based decision.